A Phase 1, Open-Label, Dose Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Trial Profile

A Phase 1, Open-Label, Dose Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 May 2017

At a glance

  • Drugs MIP 1095-I-131 (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 May 2017 According to a Progenics Pharmaceuticals media release, dosing has commenced in this trial.
    • 14 Feb 2017 Planned number of patients changed from 30 to 40, according a Progenics pharmaceuticals media release.
    • 04 Aug 2016 According to Progenics media release, this trial is expected to initiate in the fourth quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top